Losing Lipitor in the Great White North won't kill Pfizer. With sales of about $1.2 billion in Canada, the drugmaker stands to lose about 10% of Lipitor's sales. But Pfizer's acquisition of Wyeth last year made it less dependent on the drug. Those Canadian sales make up less than 2% of expected revenue for this year, and Pfizer had already factored the loss into its guidance.
U.S. sales could suffer if generic versions of Lipitor slip over the border, but only slightly. Cheaper brand-name drugs in Canada don't dent U.S. sales much.
The big loss of revenue will come in November 2011, when the drug begins to face generic competition in the U.S. Stateside sales topped $5.6 billion last year, making off-brand Lipitor a major bounty for generic-drug makers like Teva, Novartis
Pfizer will try to retain revenue from some patients by launching its own generic through its established product division. But the revenue decline could still be severe; investors should be happy if the company can retain 20% to 30% of sales in a given country when Lipitor's patent protection expires.
Other cholesterol drugs, including Merck's
The only good thing about drugs gaining generic competition is that investors can see it coming; it's not as bad as a drug suddenly being taken off the market because of unforeseen side effects. Pfizer will survive the loss of Lipitor; I'm just not sure how much increased revenue from other drugs will be able to compensate for the loss.
Todd Wenning says now's the time to double down on dividends.
Pfizer is a recommendation of the Inside Value newsletter. If you're interested in picking through the wreckage for possible turnaround candidates, you should have the Inside Value team on your side. Check it out for free with a 30-day trial.
More from The Motley Fool
3 Dividend Stocks With Better Yields Than PepsiCo
The soft-drink giant offers a solid quarterly dividend, but these three promising businesses will pay you even more to own their shares.
3 Dividend Stocks That Pay You More Than ExxonMobil Does
The oil giant pays its shareholders well, but there are opportunities out there for even higher payouts.
The 1 Word That Explains Why Pfizer's Future Looks Brighter Than Its Past
The big drugmaker had a clear message at the J.P. Morgan Healthcare Conference -- and it's a good one for investors.